Back to Browse Journals » Vascular Health and Risk Management » Volume 9

Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin

Authors Steinberg H, Anderson MS, Musliner T, Hanson ME, Engel SS

Received 21 February 2013

Accepted for publication 20 March 2013

Published 29 May 2013 Volume 2013:9 Pages 273—282

DOI https://doi.org/10.2147/VHRM.S44330

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Helmut Steinberg, Matt S Anderson, Thomas Musliner, Mary E Hanson, Samuel S Engel

Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA

Abstract: The risk of death due to heart disease and stroke is up to four times higher in individuals with diabetes compared to individuals without diabetes. Most guidelines that address treatment of dyslipidemia in patients with diabetes consider diabetes a cardiovascular disease (CVD) "risk equivalent" and recommend intensive treatment of dyslipidemia for the purpose of CVD prevention. Statins (3-hydroxy 3-methylglutaryl coenzyme A reductase [HMG-CoA reductase] inhibitors) are first-line agents in achieving lipid goals as an adjunct to diet and exercise and should be used in most patients. In addition to lipid management and blood pressure control, glycemic control is a basic component in the management of diabetes. Glycemic control is achieved by combining diabetes self-management education, diet and exercise, and, where required, antihyperglycemic agents (OHAs). Persistence and adherence to therapy are critical in achieving recommended treatment goals. However, overall compliance with concomitantly prescribed OHAs and statins is low in patients with type 2 diabetes. Fixed-dose combination (FDC) therapies have been shown to improve adherence by reducing pill burden, the complexity of treatment regimen, and, potentially, cost. Based on the available evidence regarding the pharmacokinetics and the efficacy and safety profiles of each component drug, the sitagliptin/simvastatin FDC may provide a rational and well-tolerated approach to achieving better adherence to multiple-drug therapy and improved lipid lowering and glycemic control, with consequent reduction in cardiovascular risk, diabetic microvascular disease, and mortality in diabetic patients for whom treatment with both compounds is appropriate.

Keywords: statin, oral antihyperglycemic agent, diabetes, adherence, cardiovascular disease, microvascular disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Profile of secukinumab in the treatment of psoriasis: current perspectives

Roman M, Madkan VK, Chiu MW

Therapeutics and Clinical Risk Management 2015, 11:1767-1777

Published Date: 2 December 2015

Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy

Wang ZY, Chen M, Zhu LL, Yu LS, Zeng S, Xiang MX, Zhou Q

Therapeutics and Clinical Risk Management 2015, 11:449-467

Published Date: 19 March 2015

Left ventricular dysfunction in normotensive type II diabetic patients in Port Harcourt, Nigeria

Dodiyi-Manuel ST, Akpa MR, Odia OJ

Vascular Health and Risk Management 2013, 9:529-533

Published Date: 25 September 2013

The ClaudicatioNet concept: design of a national integrated care network providing active and healthy aging for patients with intermittent claudication

Lauret GJ, Gijsbers HJ, Hendriks EJ, Bartelink ML, de Bie RA, Teijink JA

Vascular Health and Risk Management 2012, 8:495-503

Published Date: 24 August 2012

Does plasmin have anticoagulant activity?

Jane Hoover-Plow

Vascular Health and Risk Management 2010, 6:199-205

Published Date: 26 March 2010